On Thursday, Shares of Duke Energy Corp (NYSE:DUK), lost -0.67% to $71.45.
Duke Energy, declared third quarter 2015 adjusted diluted EPS of $1.47, contrast to $1.40 for the third quarter of 2014. Third quarter 2015 stated EPS was $1.35, contrast to $1.80 for the same period last year.
Earnings for the third quarter of 2015 were higher than the preceding year quarterly results, primarily due to warmer weather contrast to the previous year. The company also practiced strong growth in the Regulated Utilities business, counting the impact of the recently accomplished North Carolina Eastern Municipal Power Agency (NCEMPA) acquisition.
During 2015, the company has been able to offset weakness in the International business with favorable weather, solid operational performance in the regulated business, and benefits from closing certain planned initiatives earlier than anticipated. The company has narrowed its 2015 adjusted diluted earnings guidance range from $4.55 to $4.75 per share to $4.55 to $4.65 per share.
Duke Energy Corporation, together with its auxiliaries, operates as an energy company in the United States and Latin America. It operates through three segments: Regulated Utilities, International Energy, and Commercial Power. The Regulated Utilities segment generates, transmits, distributes, and sells electricity in the Carolinas, Florida, Ohio, Kentucky, and Indiana; and transports and sells natural gas in southwestern Ohio and northern Kentucky.
Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), declined -0.96% to $60.92, during its last trading session.
Teva Pharmaceutical Industries Ltd., declared that three company-sponsored abstracts will be presented at the 2015 Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in San Antonio, Texas on November 5-9, 2015.
Data to be presented comprise a Phase III study examining the long-term effects of reslizumab on asthma-related quality of life (AQLQ) in asthma patients formerly enrolled in reslizumab safety and efficacy studies. Reslizumab is an investigational humanized anti-interleukin-5 (IL-5) monoclonal antibody (mAb) for the treatment of asthma in patients with elevated blood eosinophils who are inadequately controlled on an inhaled corticosteroid (ICS)-based regimen.
Additional data to be presented comprise a real-world analysis of symptom control, treatment satisfaction and quality of life measures in patients with perennial allergic rhinitis presently treated with QNASL® (beclomethasone dipropionate) Nasal Aerosol. A third abstract to be presented comprises data evaluating the pharmacokinetic, pharmacodynamic and safety profiles of ProAir RespiClick® (albuterol sulfate) Inhalation Powder and ProAir® HFA (albuterol sulfate) Inhalation Aerosol in pediatric patients (ages 6-11) with asthma.
“Teva is committed to delivering and further developing therapies to assist meet the needs of the millions of people who suffer from respiratory diseases,” said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. “The ACAAI Annual Scientific Meeting provides an important forum for Teva to showcase our scientific findings. This year we are happy to present data from across our respiratory portfolio and pipeline in the areas of asthma and allergic rhinitis.”
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients.
Finally, Shares of Callon Petroleum Company (NYSE:CPE), ended its last trade with -2.43% loss, and closed at $8.85.
Callon Petroleum Company, stated results of operations for the three and nine month periods ended September 30, 2015.
Highlights for the third quarter of 2015 comprise:
- Net daily production of 9,739 barrels of oil equivalent per day (“BOE/d”), an improvement of 73% contrast to the third quarter of 2014, comprised of 77% oil volume
- Adjusted EBITDA, a non-GAAP financial measure(i), of $30.2 million, representing a margin of about 70% of Adjusted Total Revenues, a non-GAAP financial measure(i)
- Adjusted Income available to common shareholders, a non-GAAP financial measure(i), of $0.05 per diluted share based on total average diluted shares outstanding of 66.3 million shares
- Discretionary cash flow per share, a non-GAAP financial measure(i), of $0.38 per diluted share based on total average diluted shares outstanding of 66.3 million shares
- Acceleration of operational plan, and related infrastructure investment, to dedicate both horizontal rigs to the Central Midland Basin, primarily targeting the Lower Spraberry shale
Callon Petroleum Company engages in the exploration, development, acquisition, and production of oil and natural gas properties in the Permian Basin in West Texas. As of December 31, 2014, its estimated net proved reserves totaled 32.8 million barrel of oil equivalent, counting 25.7 million barrels of oil and 42.5 billion cubic feet of natural gas. The company was founded in 1950 and is headquartered in Natchez, Mississippi.